Abstract
After disappointing results from all efficacy trials conducted to date, the field of microbicides research now faces substantial challenges. Poor coordination among interested parties and the choice of nonvalidated scientific targets for phase III studies have hampered progress and created mistrust about the use of microbicides as a method to prevent HIV-1 sexual transmission. Although new promising strategies are available, there will need to be serious reappraisals of how decisions are made to advance the next generations of candidates into clinical trials, and the use of appropriate animal models in this process will be critical.
MeSH terms
-
Administration, Intravaginal
-
Animals
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / pharmacology
-
Anti-HIV Agents / therapeutic use
-
Anti-Infective Agents, Local / administration & dosage*
-
Anti-Infective Agents, Local / pharmacology
-
Anti-Infective Agents, Local / therapeutic use
-
Clinical Trials as Topic
-
Disease Models, Animal
-
Drug Evaluation, Preclinical
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy
-
HIV Infections / prevention & control*
-
HIV Infections / transmission
-
HIV-1 / drug effects*
-
Humans
-
Male
-
Patient Compliance
-
Polyelectrolytes
-
Polymers / administration & dosage*
-
Polymers / pharmacology
-
Polymers / therapeutic use
-
Primates
-
Reverse Transcriptase Inhibitors / administration & dosage*
-
Reverse Transcriptase Inhibitors / pharmacology
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Vaginal Diseases / drug therapy
-
Vaginal Diseases / prevention & control*
Substances
-
Anti-HIV Agents
-
Anti-Infective Agents, Local
-
Polyelectrolytes
-
Polymers
-
Reverse Transcriptase Inhibitors
-
polyanions